- Home
- NXGL vs KPRX Comparison
NXGL vs KPRX Comparison
Compare NXGL & KPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NXGL | KPRX |
|---|---|---|
| Founded | 1997 | 1998 |
| Country | United States | United States |
| Employees | 19 | 13 |
| Industry | Medical/Dental Instruments | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.8M | 10.7M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | NXGL | KPRX |
|---|---|---|
| Price | $0.59 | $2.53 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $2.00 | ★ $10.00 |
| AVG Volume (30 Days) | ★ 307.8K | 60.9K |
| Earning Date | 05-11-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $50.77 | N/A |
| Revenue Next Year | $46.15 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.48 | $1.76 |
| 52 Week High | $2.89 | $4.18 |
Technical Indicators
Market Signals| Indicator | NXGL | KPRX |
|---|---|---|
| Relative Strength Index (RSI) | 52.00 | 54.21 |
| Support Level | $0.57 | $2.25 |
| Resistance Level | $0.86 | $2.51 |
| Average True Range (ATR) | 0.05 | 0.16 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 90.11 | 46.34 |
Price Performance
Historical ComparisonAbout NXGL NexGel Inc
NexGel Inc manufactures high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company specializes in custom gels by capitalizing on proprietary manufacturing technologies. The gels and consumer products are manufactured using proprietary and non-proprietary mixing, coating and cross-linking technologies.
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.